|
WO2011012306A2
|
|
Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
|
|
WO2011098095A1
|
|
Peptides binding the tpo receptor
|
|
EP2125863A1
|
|
Method for forming disulfide bridges
|
|
WO2008028645A1
|
|
Peptides binding the tpo receptor
|
|
BRPI0709014A2
|
|
modified molecules that promote hematopoiesis
|
|
ZA200808289B
|
|
Modified molecules which promote hematopoiesis
|
|
US2009081145A1
|
|
Process for forming disulphide bridges
|
|
WO2008061563A1
|
|
Peptides for the treatment of multiple sclerosis
|
|
EP1897888A1
|
|
Peptides binding the TPO receptor
|
|
EP1907417A2
|
|
Supravalent compounds
|
|
CN101248086A
|
|
Supravalent compounds
|
|
BRPI0611745A2
|
|
Supravalent compounds
|
|
EP1831241A2
|
|
Method for solid-phase peptide synthesis and purification
|
|
CN101056886A
|
|
Molecules which promote hematopoiesis
|
|
AU2005303887A1
|
|
Molecules which promote hematopoiesis
|
|
MX2007005640A
|
|
Molecules which promote hematopoiesis.
|
|
WO2005090389A2
|
|
Isosteric transformation
|
|
EP1716419A2
|
|
Method for the detection of autoantibodies against specific peptides and its use in diagnosis and treatment of pregnancy-loss or infertility.
|
|
US2006128618A1
|
|
Molecules which promote hematopoiesis
|
|
WO2005040202A2
|
|
Stabilized alpha-helical peptides
|
